Pharma BD Deal Intelligence

Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals Inc.

2013 · Acquisition/Merger · $886M · Complete

Announcement Sentiment

Skeptical

Otsuka to acquire Astex at $8.50/share cash (~$886M); brings SGI-110 hypomethylating agent and Pyramid fragment-based platform plus oncology/CNS pipeline.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Pipeline outcome

Mixed

Assessment window: 10yr post-close.

Key facts

Announced Sep 04, 2013
Closed Oct 11, 2013
Deal value $886M
Deal type Acquisition/Merger
Therapeutic area Acute myeloid leukemia (AML), MDS, ovarian, liver
Indications Acute myeloid leukemia (AML), MDS, ovarian, liver
Key assets SGI-110 (guadecitabine); Pyramid fragment-based discovery platform
Mechanism DNA hypomethylating agent (DNMT inhibitor); fragment-based drug discovery

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals